The Review Of
DIABETIC
STUDIES OPEN ACCESS

The Transformative Role Of Droplet Digital PCR In The Clinical Laboratory: Principles, Applications, And Implementation Considerations For Diagnostics

Fahad Ayed Baqan Al-Anzi[1], Maryam Mustafa Abu Talib Al-Hassani[2], Fareaa Ali Abu Talib Al-Hassani[3], Abdullah Abdulkalq Al-Shamrani[4], Eissa Ali Eissa Alsawari[5], Haneen Madailah Aldirbas[6], Shrouq Faisal AlHazmi[7], Fatima Mohammed Alghamdi[8], Mashael Nashi Almutairi[9], Murad Radan Muslim Al-Mutairi[10], Noura Nasser Al-Musra11,Haya Saad Abdullah Al-Otaibi[12], Manawer Breit Al-Awti Al-Anzi[13]

[1]*Laboratory Specialist, Ministry Branch in Riyadh, KSA*
[2]*Laboratory Medicine, South Al-Qunfudhah General Hospital, Makkah, KSA*
[3]*Laboratory Medicine, South Al-Qunfudhah General Hospital, Makkah, KSA*
[4]*Laboratory Specialist, Branch of the Ministry of Health in Riyadh Region, KSA*
[5]*Laboratory Technician, Qatif Central Hospital, Estrin Province, Ksa*
[6]*Laboratory specialist, Riyadh regional laboratory, Riyadh, KSA*
[7]*Laboratory specialist, Riyadh regional laboratory, Riyadh, KSA*
[8]*General Laboratories, Al-Iman General Hospital, Riyadh, KSA*
[9]*Medical Laboratories, Al-Majmaah Region, KSA*
[10]*Laboratory Technician, General Directorate of Health Affairs in Riyadh, Ministry Branch, Riyadh, KSA*
[11]*Master's Degree in Clinical Chemistry Laboratory, General Directorate of Health Affairs, Riyadh, KSA*
[12]*Laboratory Technician, King Abdulaziz Specialist Hospital, Taif, KSA*
[13]*Medical Laboratories Technician, Arar Children's Hospital, KSA*

Abstract

Droplet digital Polymerase Chain Reaction (ddPCR) represents a critical evolutionary leap in nucleic acid quantification, moving beyond the inherent limitations of relative measurement methods toward delivering high-precision, absolute target measurement (1). This review outlines the technological foundation, analytical advantages, and crucial clinical applications of ddPCR, specifically addressing the practical implementation challenges relevant to laboratory specialists and technicians. The core methodology of ddPCR involves partitioning the sample into thousands of discrete, nanoliter-sized reaction chambers—microdroplets—and then quantifying the number of positive reactions based on the Poisson distribution (2). Key analytical characteristics of ddPCR include notably high sensitivity for targets present in low abundance, robust specificity, exceptional reproducibility, and a good tolerance to PCR inhibitors when compared with conventional molecular methods (3, 4). These characteristics render ddPCR a valuable tool across diverse clinical fields. In infectious disease diagnostics, ddPCR enables accelerated turnaround time (TAT) for highly consequential conditions such as bloodstream infections and permits precise monitoring of low-level viral reservoirs (5). In oncology, ddPCR provides high-resolution copy number variation (CNV) analysis, which is critical for stratifying clinical outcomes and guiding targeted therapies in cancers, including advanced prostate cancer (6, 7). However, the implementation of ddPCR in clinical laboratories requires careful consideration of the substantial initial investment and the critical necessity for standardized assay validation protocols covering the Limit of Detection (LOD) and Limit of Quantification (LOQ) to ensure reliable and widespread clinical adoption (8, 9).

Keywords Droplet Digital PCR; Absolute Quantification; Copy Number Variation (CNV); Infectious Disease Diagnostics; Clinical Laboratory; Assay Validation; Liquid Biopsy.

Introduction

1. Background: The Transition to Absolute Quantification

The field of molecular diagnostics demands ever-increasing precision and sensitivity, particularly as clinicians rely on increasingly subtle molecular signals—such as circulating tumor DNA (ctDNA) or residual viral load—to guide complex therapeutic decisions. The established molecular technique, quantitative PCR (qPCR), has served as the backbone of clinical nucleic acid quantification for decades. However, its fundamental reliance on relative measurement has necessitated the adoption of superior quantification methodologies to address the demands of modern precision medicine.

1.1. Limitations of Conventional Quantitative PCR (qPCR)

Traditional qPCR determines the concentration of a target nucleic acid using an ‘analog’ measurement method, wherein the Cycle Threshold (C_{T}) values are compared against a standard curve generated from known concentration references (10). This approach introduces inherent analytical vulnerabilities. The necessity of relying on external calibrators, often generated using unstable cell lines or plasmids, introduces instability and day-to-day variability into the quantification process (2).
Moreover, C_{T} data derived from qPCR is highly sensitive to fluctuations in template quality, variations in PCR efficiency, and specific experimental conditions (10). Consequently, qPCR data generated in one laboratory often proves challenging to compare directly with results generated in a different setting. This inherent lack of standardized, cross-platform comparability creates a significant challenge for establishing unified clinical guidelines and for ensuring consistency in multi-center clinical trials.
The analytical deficiency is particularly acute when dealing with samples containing very low concentrations of the target molecule. In these situations, qPCR shows extreme inaccuracy and instability, hindering the reliable detection of contaminants or rare targets (10). This instability near the analytical limit prevents qPCR from reliably quantifying clinically critical parameters such as minimum residual disease (MRD) or persistent viral reservoirs, where precision in low-abundance detection is non-negotiable. The fundamental dependency of qPCR on a relative standard curve introduces cumulative errors stemming from fluctuating reaction efficiencies. This fundamental challenge—the standardization gap—necessitated a technological shift toward a method that could decouple quantification from amplification kinetics.

1.2. Historical Context and the Genesis of Digital PCR

The conceptual basis for digital PCR (dPCR) predates modern microfluidics. The foundational idea involves partitioning a sample to the level of single molecules, performing PCR amplification on these isolated molecules, and then analyzing the resulting digital (all-or-none) signal (11). This technique was initially referred to as "single molecule PCR" or "limiting dilution PCR" (11). Saiki et al. were among the first to employ this approach in 1988, limit diluting samples to amplify single β-globin molecules for detection. While they successfully demonstrated that virtually every target molecule was amplifiable, they did not conceptualize using the frequency of detection of single molecules as a dedicated tool for quantification (11).

Early dPCR systems emerged in the mid-1990s, driven by advancements in microfabrication techniques, which allowed the production of devices with feature sizes as small as a few microns. These systems utilized microarray dPCR, partitioning reactions into micro-chambers (12). However, this first generation of microfabricated dPCR was technologically constrained. These systems were limited by a low number of individual partitions per sample, required larger reaction volumes, and demanded increased hands-on time. Furthermore, running these digital PCR assays was prohibitively costly, sometimes reaching several hundred dollars per reaction, a significant barrier compared to the low cost of traditional end-point or real-time PCR (12).

The resistance to widespread dPCR adoption was thus primarily due to technological and economic constraints—specifically, limitations on throughput and cost. This resistance was overcome by the development of microfluidic droplet technology. The transition to droplet-based microfluidics successfully addressed these early limitations, enabling the creation of modern droplet digital PCR (ddPCR) platforms. Droplet technology allowed for a massive increase in the number of partitions (often up to 20,000 per sample) at a substantially reduced reagent volume (picoliter or nanoliter scale), dramatically improving cost-effectiveness and scalability. This refinement established ddPCR as a scientifically robust and clinically viable method (2, 12).

2. Fundamental Principles and Technological Superiority of Droplet Digital PCR

The transformative power of ddPCR lies in its unique physical and computational methodology, which fundamentally differentiates it from analog PCR methods. The technique relies on physically separating the sample into thousands of independent, isolated reactions, transforming a measurement of concentration into a count of discrete positive events.

2.1. Mechanism of Droplet Partitioning and Digital Signal Generation

Droplet digital PCR employs advanced microfluidic technology to precisely manipulate fluids on the submicron scale, a promising approach for nucleic acid testing (NAT) reactions (2). Standard methods for droplet generation often utilize techniques such as T-junction or flow-focusing geometry to shear the reaction mixture into an emulsion consisting of thousands of nanoliter-sized water-in-oil droplets (2).
For example, the QX200™ Droplet Digital PCR System requires a dedicated Droplet Generator instrument, which is used to partition the ddPCR reaction mix into thousands of discrete reaction vessels (13). Within this process, the target nucleic acid molecules—DNA or RNA—are stochastically encapsulated within the microdroplets. This physical dilution ensures that most positive droplets contain either zero or one copy of the target molecule (2). This compartmentalization is key to the robustness of the assay.
Following standard thermal cycling, where amplification occurs independently within each droplet, the analysis is performed by the Droplet Reader (13). The droplets from each sample are streamed single file past a two-color optical detection system. The instrument sequentially analyzes the droplets, distinguishing and counting PCR-positive (fluorescent) and PCR-negative (non-fluorescent) droplets (13).
The physical isolation of the reaction mixture through partitioning serves a crucial function beyond mere counting: it inherently enhances reaction robustness and minimizes the effects of inhibition. In a bulk qPCR reaction, inhibitors present in the sample matrix (common in complex clinical samples like biopsies or cell-free DNA) can affect the efficiency of all amplification reactions, leading to C_{T} delays and resulting in under-quantification. Conversely, in ddPCR, the presence of an inhibitor might only cause a failure in the small number of droplets where the inhibitor is concentrated. Since quantification relies on the statistically derived ratio of the positive count from the vast majority of unaffected droplets, ddPCR maintains a good tolerance to PCR inhibitors and competitive effects found in duplex assays, thus providing more precise and accurate analysis than qPCR, especially for complex or difficult sample types (3, 14). This compartmentalization of inhibition shifts the analytical challenge from optimizing complex reaction kinetics to ensuring high-quality partitioning, inherently improving cross-laboratory comparability, which is essential for establishing standardized clinical measurements.

2.2. Absolute Quantification via Poisson Statistics

The fundamental superiority of ddPCR stems from its ability to provide absolute quantification of target nucleic acids without the reliance on an external standard curve (10). Concentration is determined computationally, calculated from the ratio of positive (amplified) partitions to the total number of partitions using the Poisson distribution statistical model (2, 11).

This approach eliminates the inherent instability associated with traditional qPCR methods. ddPCR bypasses the instability of external calibrators and the resulting day-to-day variability in quantification that plagues qPCR (2). The resulting quantification is based on the direct counting of positive events (positive partitions), which ensures that the results are highly replicable and inherently more comparable between different tests, different runs, and different laboratories than relative C_{T}-based data (10).

The capacity of ddPCR to provide absolute copy number concentration makes it ideally suited to function as a metrological reference standard. For instance, ddPCR has been successfully deployed to standardize conventional RT-qPCR methods, such as measuring reference materials for the Ebola RNA virus. This highlights the technology's reliability and precision for calibrating other quantitative molecular tests, underscoring its utility far beyond routine diagnostics and positioning it as a foundational tool for molecular quality control and standardization (3).

2.3. Analytical Superiority: Comparison to Real-Time PCR

ddPCR is globally characterized by its high sensitivity, strong specificity, and high reproducibility (3, 4). When evaluating ddPCR against qPCR, comparative studies reveal specific analytical trade-offs. While qPCR may offer a wider linear dynamic range and potentially shorter analysis time, making it suitable for initial screening applications, ddPCR consistently delivers lower variability and more precise and accurate analysis (14).

ddPCR systems have been refined specifically to detect nucleic acids present in low abundance (4). It exhibits superior sensitivity and accuracy compared to qPCR, particularly when concentrations are very low, such as in the detection of low-copy number Merkel cell polyomavirus in formalin-fixed, paraffin-embedded (FFPE) biopsies (3). The difference in sensitivity arises from the mechanism itself: ddPCR enables the measurement of thousands of independent amplification events within a single sample (the individual droplets), whereas qPCR only offers a single bulk measurement per sample, limiting its ability to resolve minute concentration differences (10).

The difference in analytical performance is summarized in the table below, emphasizing the superiority of ddPCR in areas requiring high precision and absolute measurement, which are the cornerstones of clinical molecular diagnostics.

Table 1: Comparison of Key Analytical Characteristics: ddPCR vs. qPCR

Characteristic	Droplet Digital PCR (ddPCR)	Quantitative PCR (qPCR)	Relevant Citation
Quantification Method	Absolute Quantification (Poisson distribution)	Relative Quantification (Standard Curve/C_{T})	(2, 10)
Sensitivity for Low Abundance	Extremely High, accurate even at very	Moderate, prone to inaccuracy and	(4, 10)

	low concentration	instability at low concentration	
Reproducibility & Comparability	High, due to direct counting; comparable across labs	Variable, highly dependent on template, efficiency, and conditions	(10)
Tolerance to Inhibitors	Good tolerance to PCR inhibition and competitive effects	Moderate, susceptible to competitive effects	(3, 14)
Workflow Speed	Generally limited by sequential readout time (flow cytometry heritage)	Shorter analysis time, suitable for initial screening	(14, 15)

3. Critical Applications in Infectious Disease Diagnostics

The high sensitivity, rapid turnaround time (TAT), and robust tolerance to inhibitors offered by ddPCR make it an ideal tool for infectious disease diagnostics, especially when conventional methods are too slow or lack the requisite sensitivity for low-level or persistent infections.

3.1. Accelerated Diagnosis of Bloodstream Infections (BSIs)

Accurate and timely etiological diagnosis is paramount in managing bloodstream infections (BSIs), which are associated with high disability and mortality rates (5). Traditional blood culture methods, while foundational, often require several days to yield definitive identification, delaying appropriate therapeutic intervention (16).

A prospective cohort study comparing a ddPCR assay with traditional blood culture revealed the significant performance advantages of the molecular method. The overall detection rate of ddPCR (30.28%) was found to be significantly higher than that of traditional blood culture (11.27%), resulting in an impressive extra detection rate of 19.01% (17). Critically, ddPCR dramatically shortens the Turnaround Time (TAT) for BSI pathogen identification from several days—required for traditional bacterial culture—to a rapid 4 to 5 hours (16).

The clinical implication of this accelerated TAT is profound. The capability of ddPCR to yield highly reliable results within hours, rather than days, fundamentally transforms the clinical management of sepsis. This rapid data availability allows for much earlier optimization or de-escalation of empirical antimicrobial therapy, directly supporting aggressive antimicrobial stewardship programs (17). Earlier definitive therapy, based on molecular confirmation, is a significant quality improvement measure that can reduce patient morbidity and mortality associated with prolonged broad-spectrum antibiotic use.

The study further highlighted ddPCR's reliability, even in challenging clinical scenarios. In patients definitively diagnosed with BSIs, ddPCR achieved an overall sensitivity of 85.71% (17). Notably, the sensitivity reached 100% in patients who had not yet received empirical treatment. Even in empirically treated patients, where traditional culture sensitivity drops sharply, ddPCR maintained a high sensitivity of 71.43% (17). Moreover, in cases where ddPCR was positive but blood culture was negative (ddPCR-positive/culture-negative), 74.19% of these results were consistent with the final clinical diagnosis, successfully identifying 10 different bacteria and fungi (17). This indicates that ddPCR can detect residual

DNA or RNA of pathogens that have been suppressed or cleared from circulation but were the true cause of the infection, providing crucial diagnostic information that culture cannot retrieve (17).

3.2. High-Sensitivity Viral Load Quantification and Reservoir Monitoring

The superior analytical stability of ddPCR at low concentrations is vital for monitoring chronic and latent infections. ddPCR is widely adopted for the direct quantification and clonal amplification of DNA, particularly benefiting the detection of pathogens associated with latency, such as human immunodeficiency virus (HIV), Ebola virus, malaria, and tuberculosis. These pathogens sometimes exist in plasma at concentrations too low to be reliably determined by traditional methods, necessitating the high sensitivity of ddPCR (10).

For diseases like HIV, ddPCR is essential for quantifying the persistent viral reservoir, which is a critical measure for monitoring the effectiveness of antiretroviral therapies and for advanced disease eradication studies (2). The concentration of pathogens in plasma is often quantitatively correlated with disease severity (10). Therefore, the accurate absolute quantification provided by ddPCR offers a powerful prognostic and predictive clue for effective disease treatment and management.

Other examples of ddPCR's application in viral load monitoring include:

- **Human Papillomavirus (HPV):** High-sensitivity ddPCR has been used to detect HPV E7 DNA in 87% of serum specimens from patients with associated invasive carcinomas (2). Furthermore, quantification of the HPV viral load by ddPCR may be informative for stratifying clinical outcomes in HPV-positive oropharyngeal cancer patients (3).
- **Hepatitis B Virus (HBV):** ddPCR has shown high sensitivity and specificity in measuring the copy number of HBV covalently closed circular DNA (cccDNA) in formalin-fixed, paraffin-embedded (FFPE) hepatocellular carcinoma tissue (2).
- **Viral and Pathogen Reference Standardization:** Due to its absolute counting method, ddPCR is valuable for standardizing standard RT-qPCR methods, such as measuring reference materials for the Ebola RNA virus (3).

3.3. Expanding Applications in Surveillance and Transplant Monitoring

The ability of ddPCR to provide stable absolute quantification is fundamentally important for translating pathogen load into a reliable prognostic indicator. Unlike relative measures, the absolute copy number provides a quantitative baseline against which the success of treatment can be objectively measured, moving the diagnostic function toward a predictive monitoring tool for recurrence or disease staging (10).

Beyond acute infectious disease, ddPCR is finding important roles in public health and transplant medicine. ddPCR has been utilized for noninvasive monitoring of graft integrity following Liver Transplantation (LTx), particularly in HCV patients (2). Measurement of plasma-derived cell-free DNA (GcfDNA) showed that GcfDNA results obtained via ddPCR had high sensitivity compared to conventional liver function enzymes, potentially reducing the duration needed to discriminate acute rejection in LTx patients by 7 to 14 days (2).

Furthermore, the technology's high sensitivity and accuracy are leveraged in environmental monitoring, allowing laboratories to test a wide variety of environmental samples, including soil and water, for pathogen detection (13). It is also employed for the routine evaluation of genetically modified organisms (GMOs) in food testing using validated ddPCR methods (13). The superior precision and sensitivity of dPCR are also highlighted in its growing role in environmental surveillance, particularly in wastewater monitoring, underscoring its importance in public health protection (18).

4. ddPCR in Oncology and Copy Number Variation (CNV) Analysis

In oncology, the accurate quantification of rare genetic aberrations is critical for diagnosis, prognosis, and therapeutic stratification. ddPCR is uniquely positioned to handle the challenges presented by tumor heterogeneity and low-frequency mutations in liquid biopsy samples.

4.1. Rare Mutation Detection and Liquid Biopsy

ddPCR offers the superior sensitivity and resolution required to measure varying degrees of cancer mutations and to detect rare DNA target copies within a complex genomic background (13). This analytical capability is directly transferable to the detection of circulating tumor DNA (ctDNA) in liquid biopsies (2).

Liquid biopsy, which often involves testing blood samples for cell-free DNA (cfDNA), microRNAs, and/or viral nucleic acids, is increasingly important for cancer management. ddPCR is highly beneficial in detecting these components in liquid biopsies, especially for early-stage diseases like prostate cancer (2). The high sensitivity of ddPCR is not merely a technical advantage; it is a clinical requirement for monitoring minimum residual disease (MRD) following therapy. Since ctDNA often constitutes less than 0.1% of total cfDNA, the extreme accuracy of ddPCR at very low concentrations allows clinicians to detect residual disease earlier than conventional methods, thereby guiding crucial decisions regarding treatment modification (10, 13).

Moreover, ddPCR is utilized in the quality control and quantification of sequencing libraries. It enables accurate quantification and qualification of Next Generation Sequencing (NGS) libraries without the requirement of generating a standard curve, streamlining the preparation workflow for advanced genomic analysis (13).

4.2. High-Resolution CNV Analysis: The BRCA1/2 Case Study

Copy Number Variations (CNVs) are fundamental genomic aberrations in cancer, and their accurate measurement is essential for identifying patients eligible for targeted therapies. ddPCR excels in resolving CNVs and is extensively used in cancer biomarker studies (13).

Studies have demonstrated that ddPCR provides a more sensitive and reliable approach for CNV detection compared to traditional techniques, such as Multiplex Ligation-dependent Probe Amplification (MLPA), especially when analyzing heterogeneous tissue samples where the target fraction may be low (6, 7).

A particularly illustrative application is the detection of $BRCA1$ and $BRCA2$ CNVs in advanced prostate cancer patients, where accurate detection informs the use of poly(ADP-ribose) polymerase (PARP) inhibitors (6). The study in question provided definitive evidence that ddPCR could effectively reclassify cases that yielded ambiguous results via MLPA, resolving diagnostic uncertainty and guiding therapeutic intervention (6).

Detailed findings from the CNV analysis for BRCA1/2 demonstrated the analytical power of ddPCR (19):

- **Consistency:** The deletion copy number results for both BRCA1 (CNVs = 1.2 ± 0.1) and BRCA2 (CNVs = 1.1 ± 0.2) were consistent between MLPA and ddPCR.
- **Resolution of Ambiguity:** Ambiguous MLPA results were observed in two cases of BRCA1 detection (1.2 ± 0.1) and one case of BRCA2 detection (1.3 ± 0.04). ddPCR analysis showed no significant difference between the ambiguous MLPA groups and the confirmed deletion groups for either BRCA1 or BRCA2 (19). This high-resolution capability allowed the ambiguous cases to be definitively categorized as deletions.
- **Classification:** The CNV values obtained from ddPCR analysis in advanced prostate cancer patients exhibited significant two-cluster groups (normal versus deletion), confirming the method's robustness for classifying CNV status based on absolute copy number identification (19).

The ability to resolve ambiguous CNV status holds profound clinical significance. Accurate BRCA1/2 deletion status directly influences the eligibility for crucial targeted therapies. ddPCR's superior resolution provides the necessary certainty for molecular pathologists to make definitive calls, mitigating diagnostic uncertainty and maximizing therapeutic opportunities for patients where traditional methods were inconclusive (6, 19).

4.3. Expanding Multiplexing and Cost-Effectiveness in CNV

While ddPCR offers superior analytical performance, implementation strategies must address cost-effectiveness, especially for high-volume clinical assays. Historically, targeted quantification of genetic aberrations has often relied on expensive two-color fluorescent oligonucleotide probe (TaqMan) designs (21).

A key advancement in laboratory flexibility and cost management is the ability of ddPCR technology to utilize single-color detection methods for quantifying both CNVs and point mutations (20). By employing the non-specific DNA-binding dye EvaGreen (EG), multiplexing can be achieved through the manipulation of the length of the target and reference amplicons (21). This technique allows the fluorescent signals of the target and reference products to be distinguished and quantified independently (21).

The use of EvaGreen assays significantly reduces the reliance on costly, custom-labeled fluorescent oligonucleotide probes, thereby improving the cost-effectiveness of copy number determination (20, 21). This flexibility in assay chemistry—specifically, the combination of superior precision with inexpensive dyes—is vital for making routine high-volume CNV testing economically feasible, balancing the high initial cost of the instrument with a lower reagent cost per reaction.

5. Laboratory Implementation, Workflow, and Standardization

Successful integration of ddPCR into a clinical diagnostic environment depends heavily on streamlined workflows, comprehensive instrument support, and stringent analytical validation protocols enforced by regulatory bodies.

5.1. Instrumentation and Standard Workflow

Commercially available ddPCR systems, such as the Bio-Rad QX200™, are now widely integrated into both research laboratories and clinical hospitals (13, 4). A typical QX200 system allows for the processing of up to 96 samples per run (13). The standard workflow consists of three major stages:

1. **Droplet Generation:** The ddPCR reaction mix is partitioned into thousands of nanoliter-sized droplets using the Droplet Generator (13).
2. **Thermal Cycling:** The droplets undergo standard PCR amplification on a conventional thermal cycler.
3. **Droplet Reading and Analysis:** The droplets are individually analyzed on the Droplet Reader, which counts the PCR-positive and PCR-negative droplets in a serial manner, providing absolute quantification (13).

To address the need for scalability and reduced manual intervention, automated droplet generation systems, such as the QX200 AutoDG, have been developed. These systems reduce hands-on time, offering a scalable workflow where a single instrument can continuously supply multiple Droplet Readers (8).

Looking forward, the evolution from traditional ddPCR to nanoplate dPCR systems is redefining throughput limitations. Nanoplate systems offer substantially faster workflows by enabling the simultaneous reading of all sample partitions, coupled with front-end automation and an easier, qPCR-like plate setup. This added speed makes these newer platforms increasingly suitable for high-throughput screening applications without compromising the fundamental precision and accuracy of digital PCR (22).

5.2. Analytical Validation and Quality Control (QC)

For molecular diagnostics, particularly in the United States, laboratories must adhere to rigorous regulatory frameworks. Quantitative ddPCR assays developed by the laboratory (Laboratory-Developed Tests, or LDTs) must be validated based on criteria set by the Clinical Laboratory Improvement Act (CLIA) regulations for clinical chemistry and the matching Clinical and Laboratory Standards Institute (CLSI) guidelines (9).

Comprehensive validation of a quantitative molecular assay requires meticulous evaluation of several key parameters (9):

- **Limit of the Blank (LOB):** The highest measurement result that is likely to be observed for a blank sample.
- **Limit of Detection (LOD):** The lowest quantity of analyte that can be detected reliably.
- **Limit of Quantification (LOQ):** The lowest concentration at which the analyte can not only be reliably detected but also quantified with acceptable precision and accuracy.
- **Imprecision:** Evaluation of intra-assay (within run) and inter-assay (between runs) variability.

The inherent superior sensitivity of ddPCR means that defining the true LOD and LOQ is critical. Since ddPCR provides absolute quantification without reliance on a standard curve, validation demands precise evaluation of stochastic variability near the limit of detection. This requires meticulous adherence to CLSI/CLIA guidelines to ensure that rare events detected are statistically sound and clinically meaningful (9). For example, a validated ddPCR method for the identification and quantification of $Salmonella$ achieved a high degree of analytical precision, demonstrating a limit of detection of 0.5 copies/μL and a repeatability standard deviation precision ranging between 5% and 10% (23).

5.3. Ensuring Global Comparability and Standardization

A significant advantage of ddPCR is its contribution to global molecular standardization. Because quantification is based on the direct counting of positive wells, ddPCR is highly replicable and yields results that are inherently more comparable between different tests and laboratories, mitigating the variability caused by differences in PCR efficiency that plague C_{T}-based methods (10).

This reliability makes ddPCR an excellent candidate for establishing reference standards. ddPCR has been successfully utilized for the accurate measurement of reference materials, such as the Ebola RNA virus, thereby acting as a reliable tool for calibrating conventional quantitative methods (3).

However, to fully realize the clinical utility across all applications, further validation in large-scale, diverse cohorts is still required. This is necessary to optimize cutoff precision, confirm diagnostic performance across various population demographics, and comprehensively evaluate the full clinical utility of new ddPCR assays, such as those used in CNV analysis (6).

6. Operational Challenges and Future Trajectories for the Clinical Lab

While the analytical advantages of ddPCR are indisputable, the clinical adoption of this technology is moderated by several operational and financial challenges related to implementation, integration, and throughput limitations.

6.1. Financial and Integration Hurdles

The primary hurdle facing institutions considering ddPCR deployment is the substantial financial investment required for initial acquisition and assay development (24). Initial system costs can be high, with QX200 systems, for instance, ranging from $\$38,000$ to $\$55,000$ (8). Historically, running digital PCR reactions cost several hundred dollars, although this has significantly decreased with modern platforms (12).

Beyond the capital cost, the implementation of ddPCR necessitates significant workflow adjustments in the technical laboratory (24). The learning curve associated with incorporating this technology can be steep, and the initial learning phase is complicated by the demanding constraints of clinical case turnaround time (24).

A critical and often frustrating hurdle is the integration of the new digital platform with existing informatics infrastructure. Integration with the Laboratory Information System (LIS) is vital to realizing the full benefits of any digital technology within the overall pathology and diagnostic workflow (25). If integration is not seamless, the expensive endeavor fails to deliver its full potential, leaving the lab with an inefficient tool (25).

A major contributing factor to this frustration is the subpar standards regarding hardware and software implementation and the lack of interoperability (25). Consumers are rightly wary of committing significant resources to systems that rely on closed hardware and software architecture, which leaves little room for independent, third-party integration (25). This lack of interoperability poses a systemic risk: as technology rapidly evolves, poor integration practices make it challenging for existing setups to evolve alongside new software, hardware, and accessory tools (25). Furthermore, hardware and software glitches or malfunctions are sometimes more prone to occur with these sophisticated digital systems compared to established conventional methods (24).

The necessity of open, interoperable systems represents a critical institutional commitment. The financial investment in ddPCR must be justifiable by its smooth integration into the established LIS infrastructure (25). The failure of digital systems to meet consumer expectations regarding integration due to closed platforms and proprietary standards constitutes a significant operational risk that vendors must address to facilitate widespread clinical adoption.

Table 2: Challenges in ddPCR Clinical Laboratory Deployment

Challenge Domain	Specific Hurdles	Impact on Lab Operations	Relevant Citation
Financial Investment	High initial investment in hardware and assay development cost	Requires significant upfront capital; affects long-term operational budget	(24, 8)
Workflow & Personnel	Necessity for technical workflow adjustments; steep learning curve for staff	Increases hands-on time; potentially reduces initial case turnaround efficiency	(24)
Informatics Integration	Poor LIS integration standards; pervasive lack of interoperability due to closed systems	Prevents realization of full technological benefits; risk of system obsolescence	(25)
System Reliability	Increased susceptibility to software and hardware glitches/malfunctions	Disrupts high-volume workflow reliability compared to established methods	(24)

6.2. Advancements in Automation and High-Throughput Technology

Addressing the throughput limitations of early ddPCR systems is a major focus of ongoing technological development. The throughput of existing ddPCR systems is often limited by the readout process, which sequentially interrogates droplets in a manner inherited from flow cytometry (15).

Future trends aim to significantly simplify the actuation process, which will not only lower platform costs but also reduce hands-on time, supporting the widespread adoption of dPCR (15). For commercial, high-volume applications, cost-effective manufacturing is critical, leading to a preference for materials like plastic injection molding over materials such as PDMS (15).

The most disruptive advancement in scalability is the evolution to nanoplate dPCR (22). This technology fundamentally changes the scope of dPCR by offering simultaneous reading of all sample partitions, alongside front-end automation. This added speed makes nanoplate dPCR highly suitable for screening and high-throughput applications without sacrificing the technology's core precision, accuracy, and sensitivity (22).

The transition to automated and high-throughput systems demonstrates a clear market trajectory to shift ddPCR from a specialized, low-throughput confirmation tool to a generalized, high-throughput screening platform (26). This expansion will be critical for new sectors such as metagenomics and environmental surveillance, including wastewater monitoring (26). Methodological optimization and integration with innovative technologies are the key future prospects that will ensure ddPCR's continuous expansion into new clinical and public health sectors (26).

Conclusion

Droplet Digital PCR (ddPCR) has definitively secured its position as a transformative technology within the clinical molecular laboratory, providing analytical capabilities that overcome the fundamental limitations of conventional quantitative PCR (10, 2). Its basis in absolute quantification, derived from Poisson statistics, yields unparalleled precision, sensitivity, and reproducibility, establishing it as the metrological standard for measurements near the analytical limit of detection (4, 10).

The clinical utility derived from this precision is vast and impacts domains where analytical certainty is non-negotiable. In infectious disease diagnostics, ddPCR drastically accelerates the identification of pathogens responsible for high-mortality conditions like bloodstream infections, reducing the turnaround time from several days to a matter of hours. This speed, combined with superior sensitivity, even in empirically treated patients, represents a major advancement for robust antimicrobial stewardship and improved patient outcomes (17). Furthermore, its high precision is indispensable for quantifying low-abundance nucleic acids required for monitoring chronic or latent infections, such as persistent viral reservoirs (2).

In the realm of oncology and genomic analysis, ddPCR offers the high resolution demanded by precision medicine. Its superior capacity to detect rare DNA target copies is foundational for the rapidly developing field of liquid biopsy, enabling non-invasive monitoring of disease (2, 13). Crucially, ddPCR has demonstrated its capacity to resolve complex diagnostic ambiguities, such as in BRCA1/2 copy number variation analysis within heterogeneous advanced prostate cancer samples. By definitively classifying ambiguous cases as deletions, ddPCR directly informs targeted therapeutic decisions, ensuring patients receive the optimal treatment guided by high-certainty molecular data (6, 19). The simultaneous pursuit of cost-effective chemistries, particularly the use of EvaGreen assays for CNV, further enhances its economic viability for routine, high-volume clinical use (20, 21).

Despite these analytical successes, widespread adoption remains contingent upon successfully navigating significant operational challenges. Clinical laboratories must account for the substantial initial capital investment required for instrumentation and the comprehensive effort needed to validate assays according to stringent CLIA/CLSI guidelines (8, 9, 24). Moreover, systemic challenges related to software and hardware interoperability must be urgently resolved to ensure seamless, efficient integration with existing Laboratory Information Systems (LIS) (25). Without robust integration standards, the full efficiency benefits of this high-precision technology cannot be realized.

The future trajectory of ddPCR is focused firmly on increased automation, exemplified by the development of nanoplate dPCR, which promises to expand the technology's utility from specialized confirmation to generalized high-volume screening applications across clinical and public health sectors (22, 26). Ultimately, ddPCR is poised to serve not only as a means to improve the sensitivity of clinical diagnostics but also as the fundamental metrological tool necessary for standardizing molecular measurements globally, thereby solidifying its role as an indispensable platform in the modern clinical laboratory (3).

References

1. ddPCR can also be used to standardize standard RT-qPCR methods. The One-Step RT-dPCR approach was used in one study to measure the reference materials for the Ebola RNA virus. 159. The ddPCR showed a better method for the detection of a low-copy number of Merkel cell polyomavirus in FFPE biopsies. 84. Studies have shown that ddPCR can be an effective method to classify clinical outcomes in cancer patients. Quantification of HPV viral load by ddPCR may be informative for further stratifying clinical outcomes in HPV positive oropharyngeal cancer patients. 160. A list of some of the viruses detected by ddPCR is shown in Table 1. [1]
2. The article describes droplet digital PCR (ddPCR) as a high-throughput, droplet-based refinement of conventional PCR methods. In ddPCR, DNA/RNA is stochastically encapsulated inside microdroplets, which act as reaction chambers. A small percentage of these microdroplets contain one or fewer copies of the DNA or RNA target. After PCR amplification, concentrations are determined based on the proportion of nonfluorescent partitions using the Poisson distribution.... Absolute Quantification without a Standard Curve: Unlike traditional quantitative PCR (qPCR), which requires a calibration curve often generated using cell lines or plasmids, ddPCR does not rely on a standard curve for viral acid nucleic quantification. This exempts ddPCR from the limitations of calibration curves, such as the instability of external calibrators and day-to-day variability. Busby et al. proved that on average, ddPCR values were 60% of qPCR values of the 8E5 calibration standard because of the loss of human immunodeficiency virus (HIV) DNA from the 8E5 cell calibrant.... Applications in Viral Detection (Citing Specific Studies):... Quantifying Persistent HIV Reservoir: Rutsaert et al. reviewed the performance of digital PCR in the quantification and characterization of the persistent HIV reservoir.... Hepatitis B Virus (HBV): Huang et al. showed that measuring the cccDNA copy number in formalin-fixed paraffin-embedded hepatocellular carcinoma tissue is sensitive and specific.... Human Papillomavirus (HPV): The ddPCR method has been evaluated for the diagnosis of HPV DNA in serum. High-sensitivity ddPCR detects HPV E7 DNA in 61/70 (87%) serum specimens of HPV patients associated with invasive carcinomas.... Liquid Biopsy for Prostate Cancer: ddPCR may be beneficial in detecting circulating tumor DNA (ctDNA), microRNAs, and/or viral DNAs/miRNAs in liquid biopsies for prostate cancer diagnostic purposes, especially at the early stage of diseases. [1]
3. Some of the main features of ddPCR include high sensitivity and specificity, absolute quantification without a standard curve, high reproducibility, good tolerance to PCR inhibitor, and high efficacy compared to conventional molecular methods. These...source advances in ddPCR methods and their applications in viral identification. Keywords: Droplet digital PCR, microfluidic, virus. [1]
4. A study showed that ddPCR was more sensitive and accurate than qPCR; therefore, it has been finely modified to detect low-abundance nucleic acid , which might be more suitable for clinical diagnosis. Now, ddPCR has been used to detect low-abundance nucleic acids in many laboratories. According to the above-mentioned original research works, with the development of ddPCR technique, it will be proven to be a powerful tool in detecting the pathogens causing communicable diseases. Here, we show some examples to emphasize the technique advance in ddPCR (Table 1).
5. Accurate and timely etiological diagnosis is crucial for bloodstream infections (BSIs) due to their high disability and mortality. We conducted a single-center prospective cohort study to compare the digital droplet PCR (ddPCR) assay with traditional blood culture. A total of 169 blood samples from. [3]
6. These optimal thresholds allowed ddPCR to effectively reclassify the ambiguous MLPA cases into the deletion group. Overall, ddPCR could offer a more sensitive and reliable approach for CNV detection in heterogeneous tissue samples and demonstrates strong potential as a biomarker tool for guiding targeted therapy in advanced prostate cancer patients. However, further validation in larger cohorts is

necessary to optimize cutoff precision, confirm diagnostic performance, and evaluate the full clinical utility of ddPCR. droplet digital PCR (ddPCR); BRCA1; BRCA2; copy number variants (CNVs); MLPA; advanced prostate cancer. [4]

7. The study concluded that ddPCR provides more reliable and sensitive detection of BRCA1/2 CNVs in advanced prostate cancer tissues compared to MLPA, especially in heterogeneous samples. [4]
8. The Droplet Digital PCR (ddPCR™) Technology stands as...source evaluation of limit of the blank (LOB), limit of detection (LOD), limit of quantification (LOQ), intraassay and interassay imprecision. [6]
9. The advantages of ddPCR over qPCR, especially for low-abundance nucleic acids and pathogens, are detailed as follows: * Absolute Quantification: ddPCR allows for the absolute quantification of pathogens without needing a standard curve, unlike the traditional qPCR, which determines sample concentration by an 'analog' method comparing Cycle Thresholds (CTs) to a standard curve. This is important because the concentration of pathogens in plasma is correlated to the severity of the disease in certain cases, and accurate absolute quantification provides a more powerful clue for better understanding and effective treatment of diseases. * Accuracy and Stability in Low Concentration: The main difference between ddPCR and qPCR is that ddPCR may be more accurate and sensitive. qPCR shows extreme inaccuracy in the detection of contaminants in very low concentration due to the instability in low concentration template amplification. ddPCR, by contrast, is extremely accurate in very low concentrations, with much less contamination. * Higher Sensitivity and No Pre-enrichment Needed: ddPCR shows higher sensitivity and does not require a pre-enrichment for templates in extremely low concentration. A study also showed that ddPCR was more sensitive and accurate than qPCR, and has been modified to detect low-abundance nucleic acid. * Replicability and Comparability: ddPCR is highly replicable. Since it counts absolute DNA amounts by direct counting positive wells, it provides better comparable results in different tests, whereas qPCR data from different laboratories or clinical tests are not comparable due to differences in template quality, PCR efficiency, and experimental condition. Furthermore, the partitioning process in ddPCR, where the sample is divided into 20,000 nanoliter-sized droplets and individually analyzed, enables the measurement of thousands of independent amplification events within a single sample. This is a fundamental difference from qPCR, where a single sample offers only a single measurement. In summary, the article presents that ddPCR has potential in clinical diagnosis of infectious diseases, even for diseases like extrapulmonary tuberculosis where complicated and low template-containing samples are now available with ddPCR, making sampling easier.
10. To my knowledge, Saiki et al. , in an important early study of PCR published in 1988, were the first to use this approach. They limit diluted a sample of genomes containing B-globin genes in a sample of genomes from which the β-globin gene had been deleted, and showed that single β-globin molecules could be amplified and detected. The frequency of positive amplifications when analysed by the Poisson distribution suggested that virtually every β-globin molecule was amplifiable by the PCR. They were thus the first to use PCR to isolate and analyse a single molecule but they did not conceptualise in the reverse direction and use the frequency of detection of single molecules as a tool for quantification. [7]
11. The polymerase chain reaction (PCR) was invented by Kary Mullis while he was developing methods for detection of point mutations using oligonucleotides at Cetus Corporation, California. - 1.2. Limit dilution PCR. In the early 1990s, several research groups began. - 2.1. PCR meets microfluidics. In the mid-1990s, advances in microfabrication techniques had allowed the production of devices Page 3 3 Copyright ©2019 Stilla Technologies | All Rights Reserved with feature sizes as small a few microns. - 2.2. PCR in micro-droplets. - 3.1. Digital PCR in Microarrays. - 3.2. Digital PCR in Micro-droplets. After loading the PCR reaction mixture through 12 carrier inputs, the chip was thermocycled, fluorescence was detected, and the signal was processed and analyzed by the Digital PCR Analysis software. However, digital PCR technology during this time was limited by the number of individual partitions (chambers) per sample, volume of the reactions, and increased hands-on time. Moreover, digital PCR was very costly to run, with a reaction costing several hundred dollars compared to a little

over a dollar for traditional end-point or real-time PCR. [8]

12. Cancer biomarker studies and copy number variation....source the widespread adoption of dPCR. dPCR platforms currently lack the sample multiplexing capability of qPCR. 5. Detection Methods and Multiplexing Approaches in dPCR. Similarly to qPCR, dPCR uses two main types of chemistries for the detection of nucleic. [11]
13. The study, a single-center prospective cohort study, compared the digital droplet PCR (ddPCR) assay with traditional blood culture for suspected bloodstream infections (BSIs). Overall Detection Rate: The overall detection rate of ddPCR was significantly higher compared to traditional blood culture. * Traditional Blood Culture overall detection rate: 11.27% (16/142) (95% CI, 6.78 to 17.93%). * ddPCR overall detection rate: 30.28% (43/142) (95% CI, 23.01 to 38.64%). * The extra detection rate of ddPCR was 19.01% (27/142) (95% CI, 13.11 to 26.63%). Sensitivity in BSI Patients: In patients with bloodstream infections (BSIs): * ddPCR reported an overall sensitivity of 85.71% (12/14) (95% CI, 56.15 to 97.48%). * For patients without empirical treatment, the sensitivity was 100% (7/7) (95% CI, 56.09 to 100.00%). * For patients in empirically treated patients, the sensitivity was 71.43% (5/7) (95% CI, 30.26 to 94.89%). Consistency with Clinical Diagnosis: Of the cases where ddPCR was positive but blood culture was negative (ddPCR-positive culture-negative cases), 74.19% (23/31) (95% CI, 55.07 to 87.46%) were consistent with the final clinical diagnosis. This included 10 bacteria and fungi. Turnaround Time (TAT): The importance section notes that ddPCR shortens the identification of BSI-related pathogens from several days (for traditional bacterial culture) to 4 to 5 hours. [3]
14. The overall detection rate of ddPCR was significantly higher compared to traditional blood culture. [3]
15. Digital polymerase chain reaction (dPCR) has...source in early pathogen detection and identification of drug-resistant genes. [12]
16. The study's findings regarding ddPCR for BRCA1/2 Copy Number Variants (CNVs) in advanced prostate cancer, with a focus on analytical sensitivity and specificity, are detailed below: * Overall Conclusion: The study concluded that ddPCR provides more reliable and sensitive detection of BRCA1/2 CNVs in advanced prostate cancer tissues compared to MLPA, especially in heterogeneous samples. * Comparison with MLPA for Deletion CNVs:... The deletion copy number results were consistent between MLPA and ddPCR.... Three cases showed BRCA1 deletions with CNVs = 1.2 ± 0.1.... Two cases exhibited BRCA2 deletions with CNVs = 1.1 ± 0.2.... Handling of Ambiguous Results from MLPA:... Ambiguous results from MLPA were observed in two cases of BRCA1 detection (CNVs = 1.2 ± 0.1) and one case of BRCA2 detection (CNVs = 1.3 ± 0.04).... No significant differences were found between the ambiguous and deletion groups for both BRCA1/2. * Cluster Analysis and Classification: The CNV values obtained from ddPCR analysis in advanced prostate cancer patient groups exhibited significant two-cluster groups between normal and deletion for both BRCA1 and BRCA2. This finding demonstrated that ddPCR can effectively classify BRCA1/2 CNVs into two groups based on CNVs identified through K-means clustering. [4]
17. Another advantage of ddPCR technology for quantifying both CNVs and point mutations is that single-color detection methods can be used. Using the nonspecific DNA-binding dye EvaGreen, target and reference products can be individually identified and quantified (Miotke et al. 2014). The ddPCR system allows the flexibility of using one or multiple colors for the determination of copy number. The use of an EvaGreen assay increases cost effectiveness. [13]
18. The applications for ddPCR are widespread including targeted quantitation of genetic aberrations, which is commonly achieved with a two-color fluorescent oligonucleotide probe (TaqMan) design. However, the overall cost and need for optimization can be greatly reduced with an alternative method of distinguishing between target and reference products using the nonspecific DNA binding properties of EvaGreen (EG) dye. By manipulating the length of the target and reference amplicons, we can distinguish between their fluorescent signals and quantify each independently. We demonstrate the effectiveness of this method by examining copy... These microfluidic designs should also be valuable for other diagnostic and research applications, including detecting rare cells and rare mutations, prenatal diagnostics, monitoring residual disease, and quantifying copy no. variation and gene expression patterns. [14]

19. The evolution from ddPCR to nanoplate dPCR has widened the scope of this technology to include more applications. The nanoplate dPCR workflow is substantially faster thanks to the simultaneous reading of all sample partitions, front-end automation, and an easy qPCR-like plate set-up. This added speed makes it suitable for screening and high-throughput applications without compromising precision, accuracy and sensitivity. See what dPCR can do for you. Digital PCR and in particular the QIAGEN nanoplate-based technology is fundamentally changing the questions you can answer today, enabling a broad range of applications. Explore benefits. [15]
20. A simplex and duplex droplet digital polymerase chain reaction (ddPCR)-based method for the identification and quantification of Salmonella using ttr, invA, hilA, spaQ, and siiA gene sequences was validated. The method has high specificity, working interval between 8 and 8,000 cp/µL in ddPCR reaction, a limit of detection of 0.5 copies/µL, and precision ranging between 5 and 10% measured as a repeatability standard deviation. The relative standard measurement uncertainty was between 2 and 12%. This tool will improve food safety in national consumption products and will increase the competitiveness in agricultural product trade. [16]
21. Table 1. Challenges and opportunities in DP deployment in private practice. Challenges. ▪ High investment in initial deployment and development. ▪ Necessity for workflow adjustments in the technical laboratory. ▪ Time constraints in case turnaround time in the private setting make initial learning phase more difficult for pathologists. ▪ Software and hardware glitches and malfunction are more prone to happen, comparing with conventional microscopy. [17]
22. There are multiple hurdles that...source third party integration. What's more interesting and troubling is that[18]
23. Furthermore, we compare various...source with innovative technologies, and expansion into new sectors like metagenomics, are explored. [12]

Works cited

1. Droplet digital PCR of viral DNA/RNA, current progress, challenges... ,accessed December 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8013307/
2. Clinical Diagnostic Performance of Droplet Digital PCR for ... - PubMed, accessed December 1, 2025, https://pubmed.ncbi.nlm.nih.gov/36602351/
3. Droplet Digital PCR Improves Detection of BRCA1/2 Copy Number ..., accessed December 1, 2025, https://www.mdpi.com/1422-0067/26/14/6904
4. Applying Standard Clinical Chemistry Assay Validation to Droplet Digital PCR Quantitative Liquid Biopsy Testing - Oxford Academic, accessed December 1, 2025, https://academic.oup.com/clinchem/article-abstract/64/12/1732/5608655
5. Digital PCR: A brief history - PMC - NIH, accessed December 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5129430/
6. History of Digital PCR | Stilla Technologies, accessed December 1, 2025, https://www.stillatechnologies.com/wp-content/uploads/2019/08/dPCR-history-1.pdf
7. dPCR: A Technology Review - PMC - PubMed Central, accessed December 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5948698/
8. Advancing Pathogen Identification: The Role of Digital PCR in Enhancing Diagnostic Power in Different Settings - NIH, accessed December 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11311727/
9. Digital PCR for Copy Number Variation Analysis | Bio-Rad, accessed December 1, 2025, https://www.bio-rad.com/en-us/applications-technologies/digital-pcr-for-copy-number-variation-analysis
10. High Sensitivity Detection and Quantitation of DNA Copy Number and Single Nucleotide Variants with Single Color Droplet Digital PCR | Analytical Chemistry - ACS Publications, accessed December 1, 2025, https://pubs.acs.org/doi/10.1021/ac403843j
11. dPCR vs qPCR - QIAGEN, accessed December 1, 2025,

https://www.qiagen.com/us/applications/digital-pcr/beginners/dpcr-vs-qpcr
12. Validation of Droplet Digital Polymerase Chain Reaction for Salmonella spp. Quantification, accessed December 1, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01512/full
13. Digital Pathology Implementation in Private Practice: Specific Challenges and Opportunities, accessed December 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8871027/
14. Integration and Interoperability Are Essential for the Growth of Digital Pathology, accessed December 1, 2025, https://digitalpathologyassociation.org/blog/integration-and-interoperability-are-essential-for-the-growth-of-digital-pathology